The Goldman Sachs Group, Inc. 13D and 13G filings for Lumos Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 4:02 pm Sale |
2024-12-31 | 13G | Lumos Pharma, Inc. LUMO |
GOLDMAN SACHS GROUP INC GS |
0 0.000% |
-406,711 (Position Closed) |
Filing |
| 2024-02-09 7:14 pm Sale |
2023-12-29 | 13G | Lumos Pharma, Inc. LUMO |
GOLDMAN SACHS GROUP INC GS |
406,711 5.100% |
-62,691 (-13.36%) |
Filing |
| 2023-02-06 5:43 pm Purchase |
2022-12-30 | 13G | Lumos Pharma, Inc. LUMO |
GOLDMAN SACHS GROUP INC GS |
469,402 5.600% |
469,402 (New Position) |
Filing |